Search

Background: Pregnancy complicated with pulmonary artery hypertension (PAH), lies at increased risk of maternal and neonatal complications. Although studies have reported mortality rates of up to 56% associated with pregnancy in PAH, however, with a multidisciplinary approach including obstetrics, anesthesia, and cardiology, care in women with PAH has improved. It is necessary to investigate if such a modern multidisciplinary approach has led to a reduction in maternal mortality and has improved maternal and fetal outcomes. Aim: Our study evaluates maternal and fetal outcomes in pregnant women with PAH in a tertiary care setting in North Eastern India with a multidisciplinary approach. Materials and methods: This retrospective, hospital-based, time-bound study was done on 54 pregnancies complicated by PAH, over one and a half years. Patients were evaluated for the development of any cardiac complications like arrhythmia, congestive cardiac failure, thromboembolism, and atrial fibrillation. Maternal obstetric complications were evaluated like postpartum hemorrhage, anemia, and pregnancyinduced hypertension. Gestational age at delivery and mode of delivery were also noted. Fetal complications like preterm delivery, fetal growth restriction, intrauterine fetal death, and congenital cardiac disease were noted. Results: The mode of delivery was LSCS in the majority (77.7%), with the mean gestational age of delivery being 38 weeks and 5 days. On the assessment of PAH, the mild degree was seen in the majority of cases (55.6%), moderate PAH in around 29.6%, and a severe degree of PAH was seen in only 14.8% of cases. The majority of cardiac defects associated with PAH were congenital cardiac diseases in the form of ASD and VSD (68.5%). The majority of patients had spinal anesthesia (42.85%) during LSCS. General anesthesia was used in only 10 cases (23.8%). Preterm deliveries and fetal growth restriction were seen in around 14 and 33% of cases respectively, with no intrauterine fetal death. Cardiac complications occurred in 11% of cases and maternal obstetric complications occurred in 29.6% of cases. No maternal death was noted in the study group. On further analysis, it was seen that maternal complications were significantly higher among those with a higher degree of PAH (p = 0.006). Also, the baby's birth weight was significantly lower with an increase in the severity of PAH. On Bonferroni post hoc analysis, the association was between mild and severe PAH (p < 0.01) and between moderate and severe PAH (p = 0.016). Conclusion: Our study has shown no maternal mortality over a group of 54 pregnant women. This study thereby appraises the contribution of a multidisciplinary approach in the management of these patients. [ABSTRACT FROM AUTHOR]

Anaemia is a well‑known global health concern in the South Asian countries, and it is estimated that India has the utmost prevalence of anaemia and maternal deaths due to iron deficiency anaemia. This study aims to assess the efficacy and safety of intravenous ferric carboxymaltose (FCM) in antenatal women with anaemia in the second and third trimesters of pregnancy. Methods: A single‑arm prospective cohort (before–after) study among 60 antenatal women with moderate to severe anaemia in the second and third trimesters was conducted from December 2020 to December 2022, and the eligible women were given 1000 mg of intravenous FCM injection. Efficacy was assessed by rate of improvement in haemoglobin and ferritin at 2 weeks post infusion. Safety analysis was done by assessing adverse drug reactions and foetal heart monitoring during the infusion. Results: A total 60 antenatal women with a median gestational age of 32.5 weeks at presentation received 1000 mg of intravenous FCM. There was a rise in mean haemoglobin from 8.05 gm% pre‑infusion to 10.93 gm% 2 weeks post infusion, showing a mean rise of 2.88 gm%. Similar improvement was noted in mean serum ferritin levels from 25.92 pre‑infusion to 253.96 post FCM infusion. There were no reports of drug‑related major adverse effects in the mother or the foetus. Conclusions: FCM is found to be safe and effective treatment with rapid replenishment of haemoglobin and ferritin levels in a single dose, which makes it suitable and compels consideration as the first choice for treatment of iron‑deficiency anaemia. [ABSTRACT FROM AUTHOR]